Notícias e Atividades da Senhwa Biosciences
Presença
Senhwa Biosciences é uma empresa listada sob o símbolo 6492 (TW).
Executivos
Veja o organograma con seus 11 executivos principais
Biografias mais buscadas da Senhwa Biosciences
- Jin-Ding Huang, Chief Executive Officer
- Benny Hu, Chairman of the Board
- Jocelyn Lee, Director, Legal and Regulatory Affairs
Criar um alerta
para seguir os movimentos de executivos da Senhwa Biosciences.
Biotecnologia
Senhwa Biosciences possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Senhwa Biosciences
- Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma.
- Senhwa Biosciences Recognized by Europen Media as One of Taiwan’s Most Noteworthy Biotech Companies in 2025
- Senhwa Biosciences Attended Cathay Securities' Institutional Investor Conference to Update the Company's Business Operations and Future Outlook
- Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors
- Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director
- Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Neuroblastoma
- US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute
- Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
- US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma
- Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress.
- View more press releases Close
Redes sociais sobre Senhwa Biosciences
- Senhwa Biosciences na Wikipedia, Google News e Yahoo Finance
- Senhwa Biosciences na LinkedIn, Twitter e YouTube
